A retrospective cohort study to determine prognostic and predictive markers of the anticancer effect of nivolumab
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer
- Focus Pharmacodynamics; Therapeutic Use
- 02 Dec 2020 New trial record